Everolimus News and Research

RSS

Launch of EMSO rapidly accesses ground-breaking cancer research from research to practice

ESMO, the leading organization for medical oncology, has launched an important new service for rapidly disseminating research to accelerate the transition of results into practice for the benefit of cancer patients.

18 Feb 2021

Targeted drug combined with immunotherapy prolongs survival in patients with advanced kidney cancer

Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.

13 Feb 2021

Researchers call for trials of rapamycin to treat COVID-19

Researchers in the United States, China, and the UK have called for immediate large-scale clinical trials of an antibiotic called rapamycin as a prophylactic and treatment approach to coronavirus disease 2019 (COVID-19) in older individuals.

4 Feb 2021

New therapeutic strategy designed to improve kidney function after lung transplantation

The Covid-19 pandemic shows the importance of medical research in the treatment of lung diseases. The Medical University of Vienna is renowned the world over in the field of lung transplantation medicine.

23 Dec 2020

Study shows COVID-19 vulnerability increases exponentially with age

Aging-US recently published "From Causes of Aging to Death from COVID-19" by Blagosklonny et al. which reported that COVID-19 is not deadly early in life, but mortality increases exponentially with age - which is the strongest predictor of mortality.

7 Oct 2020

Experts use genomic analysis tools to create personalized treatment for kidney cancer patients

Experts at City of Hope and the Translational Genomics Research Institute are using one of the world's most comprehensive genomic analysis tools to map out personalized treatment plans for metastatic kidney cancer patients.

22 Jul 2020

Scientist proposes geroprotective strategies to reduce lethality of COVID-19 in the elderly

The Biogerontology Research Foundation, a registered UK charity supporting and promoting aging and longevity research worldwide since 2008, today announced the publication of a paper titled "Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections" in the leading journal Aging.

6 Apr 2020

Drug used for breast, renal cancers may provide survival benefit for patients with head and neck cancers

A targeted therapy drug used for breast and kidney cancers may also extend progression-free survival for patients with advanced head and neck cancer who are at high risk for recurrence after standard treatment.

27 Feb 2020

A two-drug combo that halts growth of cancer cells discovered

UT Southwestern Simmons Cancer Center researchers have discovered a two-drug combo that halts the growth of cancer cells that carry HER2 mutations.

23 Jan 2020

Synthetic mRNA nanoparticles restore tumor suppressor gene, make cancer cells susceptible to drugs

In preclinical experiments, investigators restored p53 using synthetic mRNA nanoparticles, making lung and liver cancer cells susceptible to available cancer drugs.

23 Dec 2019

Mcl-1 inhibition blocks cell survival in ER+ breast cancers

While estrogen receptor - + breast cancers express high levels of three anti-apoptotic Bcl-2 family members, pharmacological inhibition of Bcl-2 and/or Bcl-xL fails to induce cell death in ER + breast cancer cell lines, due to rapid and robust Mcl-1 upregulation.

26 Nov 2019

Rapamycin is more effective at slowing down aging, says researcher

The scientist discusses several reasons, including fear of the actual and fictional side effects of rapamycin, everolimus and other clinically-approved drugs, arguing that no real side effects preclude their use as anti-aging drugs today.

17 Oct 2019

Study: Revascularization with PCI or CABG prolongs survival in patients with left main disease

Patients with left main coronary artery disease (LMCAD) typically have a poor prognosis due to the large amount of myocardium at risk.

30 Sep 2019

IDEAL LM study: Biodegradable polymer everolimus-eluting stent safe and effective for patients undergoing PCI

New data from the IDEAL-LM trial found that a biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT) was safe and effective compared to a conventional durable polymer everolimus-eluting stent (DP-EES) followed by 12 months of DAPT in patients undergoing PCI for unprotected left main coronary artery (uLMCA) disease.

27 Sep 2019

Shorter duration DAPT after PCI did not increase adverse events in high-bleeding risk patients, finds study

Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy did not increase myocardial infarction or stent thrombosis in high bleeding risk patients treated with a contemporary drug-eluting stent.

27 Sep 2019

New combination treatment shows promise for common brain tumor in children

A new combination treatment aimed at resistant and recurrent low-grade gliomas slowed tumor growth and killed tumor cells in laboratory and mouse models.

22 Mar 2019

Physicians more likely to prescribe drugs of manufacturers who paid them money

In a study published in The Oncologist, physicians treating certain cancers who consistently received payments from a cancer drug's manufacturer were more likely to prescribe that drug over alternative treatments.

6 Feb 2019

Study shows novel strategy to reduce breast cancer bone metastasis

Uncovering a novel mechanism that promotes growth of breast cancer bone metastasis has revealed a potential Achilles' heel for these cancer cells. Reported in the journal Cancer Cell, the study shows that interfering with this mechanism can reduce the risk of relapses in animal models.

12 Nov 2018

Toxic effects of drugs in the lungs 'more widespread than thought'

A systematic review of research has revealed that the toxic effects on the lung of drugs commonly taken to treat a range of common conditions is much more widespread than thought.

29 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018